Genetic testing can identify variants that raise the risk of muscle toxicity and other adverse effects from statin therapy, helping clinicians tailor drug choice and dose. The most robust and clinically actionable marker is the SLCO1B1 gene variant linked to reduced hepatic uptake of several statins; other contributors include metabolic enzymes and drug transporters whose effects vary by statin type and patient ancestry.
SLCO1B1 and statin-associated myopathy
The SLCO1B1 c.521T>C variant reduces function of the OATP1B1 hepatic transporter, increasing circulating statin levels and risk of myopathy, especially with simvastatin. This association was highlighted by Link E and the SEARCH Collaborative Group at the University of Oxford in the New England Journal of Medicine and is incorporated into clinical guidance by the Clinical Pharmacogenetics Implementation Consortium. The U.S. Food and Drug Administration lists SLCO1B1 as a genomic biomarker on statin drug labels. Because the effect is drug-specific and dose-dependent, SLCO1B1 testing is most informative when considering high-dose simvastatin or comparing alternative statins.
CYP enzymes, ABC transporters, and population differences
Variants in CYP3A4 and CYP3A5 can alter metabolism of simvastatin and atorvastatin, while the ABCG2 Q141K variant (also called rs2231142) affects rosuvastatin pharmacokinetics and can increase systemic exposure. Findings summarized by the Clinical Pharmacogenetics Implementation Consortium and regulatory data from the U.S. Food and Drug Administration underscore that these markers modulate exposure rather than directly causing toxicity. Evidence for many variants remains incomplete or inconsistent across studies, so broad panel testing may yield uncertain clinical actionability.
Relevance, causes, and consequences
Genetic effects stem from altered transporter function or enzyme activity leading to higher systemic statin concentrations that predispose to muscle injury and, rarely, rhabdomyolysis. Clinically, identifying high-risk genotypes can prompt use of lower doses, alternative statins with different metabolic pathways, or non-statin lipid-lowering strategies. Population genetics matter: allele frequencies differ by ancestry, with some variants like ABCG2 Q141K more common in East Asian populations, a point emphasized in pharmacogenomics resources from the National Institutes of Health. Ethical, cultural, and access considerations influence whether testing is available and accepted in different health systems, which affects equitable implementation of genotype-guided statin therapy.